Home > Journals > Giornale Italiano di Dermatologia e Venereologia > Past Issues > Giornale Italiano di Dermatologia e Venereologia 1998 April;133(2) > Giornale Italiano di Dermatologia e Venereologia 1998 April;133(2):79-85

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Giornale Italiano di Dermatologia e Venereologia 1998 April;133(2):79-85

Copyright © 1998 EDIZIONI MINERVA MEDICA

language: English

Topical azelaic acid therapy for palpebral lesions of melanoma in situ (lentigo maligna) and for melanoma in situ progressed to invasive melanoma. A report on four cases

Nazzaro-Porro M. 1, Zina G. 2, Breathnach A. S. 3, Bernengo M. 1, Passi S. 4, Picardo M. 1, Balus L. 1, De Luca C. 4

1 Istituto Dermatologico S. Gallicano, Rome; 2 Clinica Dermatologica dell’Università, Turin; 3 Division of Physiology, and Institute of Dermatology, UMDS, St. Thomas’ Hospital Campus, London, U.K.; 4 Centro Invecchiamento Cellulare, Istituto Dermopatico dell’Immacolata, Rome


PDF


Aze­laic ­acid has ­been ­shown to ­have a bio­log­ical anti­pro­life­ra­tive and cyto­toxic ­effect on the abnor­mally hyper­ac­tive and malig­nant melan­o­cyte ­both in ­vivo and in ­vitro. ­Here, ben­e­fi­cial ­effects of top­ical aze­laic ­therapy on ­four ­facial ­lesions ­where sur­gery was not con­sid­ered to be a pri­mary or avail­able ­option are ­described. Two ­were ­cases of mel­a­noma in ­situ ­involving the ­lower ­eyelid. In one, com­plete regres­sion of the ­lesion was ­achieved and main­tained for six ­years. In the ­other, the ­overall ­lesional ­area was ­greatly ­reduced, ­allowing dis­crete exci­sion of ­small ­relapses ­with no recur­rences for up to ­nine ­years: ­this ­case dem­on­strates an adju­vant ­effect of aze­laic ­acid ­therapy on sur­gery, in ­reducing the ­overall ­area to be ­excised. The ­other two ­cases ­were of mel­a­noma in ­situ pro­gressed to inva­sive malig­nant mel­a­noma in ­which com­plete clin­ical regres­sion of the ­lesions was ­achieved, in one ­case for up to ­five ­years. Treat­ment in ­these ­cases was essen­tially pal­li­a­tive, ­with pro-b­able pro­lon­ga­tion of ­life in one, and cer­tainly, improve­ment in ­quality of ­remaining ­life in ­both. ­Newer for­mu­la­tions for top­ical appli­ca­tion, pos­sibly com­bined ­with ­oral or ­even ­systemic admin­is­tra­tion, ­could ­lead to ­increased ­delivery of aze­laic ­acid to ­lesional ­sites and reduc­tion in treat­ment ­time ­with sim­ilar ­cases in ­future.

top of page